摘要
非酒精性脂肪肝病已经成为全球的公共卫生问题,我国的患病人数也增长迅速。非酒精性脂肪肝的治疗药物研发引起了广泛的重视,但目前还没有药物批准上市。本文就目前非酒精性脂肪肝新药涉及的治疗靶点和机制进行概述,并着重关注了处于上市前临床研究阶段的药物和天然药物,旨在为开发出安全、有效的治疗脂肪肝药物提供参考。
Non -alcoholic fatty liver disease （NAFLD） has become a major global public health issue and NAFLD incidence increases drama- tically in China. Novel drug development against NAFLD received increased attention, although none has been approved so far. This review summarized major therapeutic targets of NAFLD and their potential molecular mechanisms, specifically emphasizing drugs currently in the clinical trials and natural medicine. Our work aims to provide references for developing safe and efficient drugs against NAFLD.
作者
王梦瑶
黄志军
WANG Meng-yao;HUANG Zhi-jun(Center of Clinical Pharmacology,The Third Xiang Ya Hospital,Central South University,Changsha 410013,China;Drug Evaluation Technology Nation-Local Joint Engineering Laboratory,Changsha 410013,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2018年第20期2452-2455,共4页
The Chinese Journal of Clinical Pharmacology
基金
国家自然科学基金资助项目(81673520)
关键词
非酒精性脂肪肝
治疗靶点
新药
临床试验
天然药物
non - alcoholic fatty liver disease
therapeutic target
new drug
clinical trial
natural medicine
